UNITED STATES

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

SCHEDULE 13G

 

 

Under the Securities Exchange Act of 1934
(Amendment No.    )*

 

ABIOMED, INC.

(Name of Issuer)

 

COMMON STOCK, $0.01 PAR VALUE

(Title of Class of Securities)

 

003654100

(CUSIP Number)

 

November 19, 2004(1)

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o

Rule 13d-1(b)

ý

Rule 13d-1(c)

o

Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

(1)  Genzyme Corporation previously reported its beneficial ownership of shares of ABIOMED, Inc. on Schedule 13D.  This Schedule 13G is being filed as a result of a determination by Genzyme that it is eligible to report its beneficial ownership of ABIOMED shares pursuant to Rule 13d-1(c).

 


 

CUSIP No.  003654100

 

 

1.

Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)
Genzyme Corporation (IRS Identification No. 06-1047163)

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)
Not applicable.

 

 

(a)

o

 

 

(b)

o

 

 

3.

SEC Use Only

 

 

4.

Citizenship or Place of Organization
Massachusetts

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5.

Sole Voting Power
2,307,692

 

6.

Shared Voting Power 
0

 

7.

Sole Dispositive Power 
2,307,692

 

8.

Shared Dispositive Power
0

 

 

9.

Aggregate Amount Beneficially Owned by Each Reporting Person
2,307,692

 

 

10.

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
Not applicable.

 

 

11.

Percent of Class Represented by Amount in Row (9)
10.6%

 

 

12.

Type of Reporting Person (See Instructions)
CO

 

2


 

Item 1.

 

(a)

Name of Issuer
ABIOMED, Inc.

 

(b)

Address of Issuer’s Principal Executive Offices
22 Cherry Hill Drive, Danvers, MA 01923

 

Item 2.

 

(a)

Name of Person Filing
Genzyme Corporation

 

(b)

Address of Principal Business Office or, if none, Residence
500 Kendall Street, Cambridge, MA 02142

 

(c)

Citizenship
Genzyme Corporation is a Massachusetts corporation.

 

(d)

Title of Class of Securities
Common Stock, $0.01 par value per share

 

(e)

CUSIP Number
003654100

 

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)

o

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

(b)

o

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

(c)

o

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

(d)

o

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

 

(e)

o

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 

(f)

o

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

 

(g)

o

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

 

(h)

o

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

(i)

o

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

(j)

o

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Not applicable.

 

3


 

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

(a)

Amount beneficially owned:
2,307,692

 

(b)

Percent of class:
10.6%

 

(c)

Number of shares as to which the person has:

 

 

 

(i)

Sole power to vote or to direct the vote
2,307,692

 

 

(ii)

Shared power to vote or to direct the vote
0

 

 

(iii)

Sole power to dispose or to direct the disposition of   

2,307,692

 

 

(iv)

Shared power to dispose or to direct the disposition of
0

 

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   o.

Not applicable

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable

 

Item 8.

Identification and Classification of Members of the Group

Not applicable

 

Item 9.

Notice of Dissolution of Group

Not applicable

 

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

4


 

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date:  November 19, 2004

GENZYME CORPORATION

 

 

 

 

 

By:

 /s/ Peter Wirth

 

Peter Wirth

 

Executive Vice President, Chief
Legal Officer and Secretary

 

5